Samsara BioCapital

Dr. Srinivas Akkaraju, the Founder and Managing General Partner, leads investment decisions. He is supported by partners Mike Dybbs and Abe Bassan, and a deep bench of venture partners — including former CFOs and R&D heads from BioMarin, Genentech, and other biopharma companies — who contribute to due diligence and portfolio-company oversight.

Samsara invests directly in operating companies and does not market itself as a fund-of-funds. Its portfolio lists over 80 private and public biotech companies, and the firm describes itself as a partner to the next generation of therapeutic companies — implying a direct-investment, company-level engagement model.

The firm targets the full biotech lifecycle: seed-stage company creation, early-stage venture rounds, expansion and late-stage financings, and public-company positions. Its portfolio includes recent IPOs such as Arcellx and Prime Medicine, as well as preclinical and clinical-stage private companies such as Kalaris Therapeutics and Tentarix Biotherapeutics.

Samsara does not publish a formal exclusion list. Its portfolio is concentrated almost entirely on human therapeutics — spanning oncology, immunology, cardiometabolic, gene therapy, and ophthalmology — with limited exposure to diagnostics and digital health. Non-therapeutic sectors such as medical devices or healthcare IT appear absent from the disclosed portfolio.

The firm has not publicly disclosed the composition of its capital base. It does not market itself as a single-family office or disclose a single wealth source, suggesting institutional and/or high-net-worth individual limited partners typical of a venture capital firm.

No separate philanthropic foundation is disclosed on the firm's website, and no public records link Samsara directly to a dedicated charitable vehicle.

The firm has not publicly detailed a formal co-investment program. Its deal participation, however, often appears alongside other venture and crossover investors — for example, in syndicates backing companies that later went public or were acquired — suggesting a willingness to co-invest as part of broader financing rounds.